Catalent, Inc. is a pharmaceutical company based in the United States with an ESG Score of 20.8. They operate as a CDMO under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent works with pharmaceutical customers through long-term supply agreements and offers development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 50 facilities worldwide, Catalent provides comprehensive services throughout the entire product life cycle. Medium-risk company.